NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
Clinical Trials
374 trialsNCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02314182 2025-12-19
GRECCAR8
Hospices Civils de Lyon
Phase 3 Completed
NCT03984578 2025-11-18
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00885066 2025-09-30
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Centre Antoine Lacassagne
Phase 1 Completed
NCT04664829 2025-09-23
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
National Cancer Centre, Singapore
Phase 1 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT02978612 2025-09-05
ACE
Oslo University Hospital
Phase 2 Completed
NCT07143097 2025-08-27
Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
Beni-Suef University
Phase 2 Completed
NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
NCT01354522 2025-06-15
TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
Peking Union Medical College Hospital
Phase 3 Completed
NCT01804790 2025-06-12
Néofirinox
UNICANCER
Phase 3 Completed
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT03396926 2025-02-28
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Phase 2 Completed
NCT04696757 2025-02-12
NORMANDY
Kangbuk Samsung Hospital
Phase 2 Completed
NCT03916510 2025-02-06
CEDAR
University of Oxford
Phase 1 Completed
NCT04518280 2025-01-17
TORCH
Fudan University
Phase 2 Completed
NCT00780494 2025-01-14
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Phase 2 Completed
NCT04534218 2024-12-20
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT02861300 2024-12-19
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03487666 2024-12-03
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Georgetown University
Phase 2 Completed
NCT04679597 2024-10-17
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure
Institute of Oncology Ljubljana
Completed
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT00483366 2024-09-23
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
University of Nebraska
Phase 1 Completed
NCT01404156 2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3 Completed
NCT02873195 2024-08-23
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT02514278 2024-08-14
GRECCAR12
University Hospital, Bordeaux
Phase 3 Completed
NCT04464174 2024-07-26
PATHFINDER
MedSIR
Phase 2 Completed
NCT02024009 2024-07-25
SCALOP-2
University of Oxford
Phase 1/2 Completed
NCT03641547 2024-07-18
CHARIOT
University of Oxford
Phase 1 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT06246461 2024-02-07
The Therapeutic Effect of Different Doses of Capecitabine
Jingjiang People's Hospital
Phase NA Completed
NCT04720131 2024-01-30
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Phase 2 Completed
NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
NCT03607656 2023-12-18
CHANGE
Shanghai University of Traditional Chinese Medicine
Phase 2/3 Completed
NCT01387295 2023-12-11
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Herlev Hospital
Phase 2 Completed
NCT02528175 2023-12-07
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer
Sunnybrook Health Sciences Centre
Phase NA Completed
NCT02754011 2023-12-07
GEP14-LEECAP
UNICANCER
Phase 1 Completed
NCT02287129 2023-11-28
MEMORI
Technical University of Munich
Phase 2 Completed
NCT03958721 2023-11-27
Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT02555358 2023-10-19
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage â…¢ Clinical Study
Hebei Medical University
Phase 2 Completed
NCT03854799 2023-10-19
AVANA
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT02017704 2023-10-17
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02551237 2023-10-13
NACRE
UNICANCER
Phase 3 Completed
NCT03156036 2023-09-07
Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC
Asan Medical Center
Phase 2 Completed